Common Stock, par value $0.0001 per share
- Symbol
- GRI
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 8.01, 9.01 · 8-K
GRI Bio, Inc.
GRINASDAQEQUITYCurrent
Regulation FD Disclosure · Other Events
Item 7.01 Regulation FD On September 8, 2026, GRI Bio, Inc. (the "Company") posted an updated corporate presentation to the Company's website at www.gribio.com/investors/events-presentations/ which is included as Exhibit 99.1 to this Current Report on Form 8-K.…
Company context
GRI Bio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for inflammatory, fibrotic and autoimmune diseases. The Company's lead program, GRI-0621, is an oral RARβ/γ-selective agonist being developed for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and life-threatening fibrotic lung disease with significant unmet need. GRI-0621 is designed to modulate pathways associated with inflammation, fibrosis and tissue repair and is being evaluated as a potential novel oral therapeutic for patients with IPF.
Current securities
Registered securities in this filing
GRI BIO, INC. · 8-K · Filed 2026-09-08
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD
On September 8, 2026, GRI Bio, Inc. (the "Company") posted an updated corporate presentation to the Company's website at www.gribio.com/investors/events-presentations/ which is included as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On September 8, 2026, the Company issued a press release announcing new translational biomarker data from the Phase 2a study evaluating GRI-0621 (oral tazarotene) in patients with idiopathic pulmonary fibrosis. The press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated into this Item 8.01 by reference.
Filed exhibits (1)
EX-99.2 3 ex992_ersrelease.htm EX-99.2 Document Exhibit 99.2 GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars New whole blood RNA sequencing data identified coordinated, consistent change in genes governing immune re-balancing, myofibroblast inhibition, fibrolysis, basement membrane repair, re-epithelialization, antitussive effect and GI protection Signals observed from at least two independent measurement modalities, including RNA sequencing, serum extracellular matrix biomarkers, spectral flow cytometry and clinical readouts, supported each of the nine pre-specified mechanistic pillars, defining a repair phenotype with anti-fibrotic and pro resolving effects Approximately 2x - 2.5x as many GRI-0621-treated patients experienced an FVC increase compared with placebo; placebo-adjusted FVC change from baseline at Week 12 was +99 mL overall and +139 mL on background standard-of-care antifibrotic therapy Totality of Phase 2a findings supports advancement of GRI-0621 in the IPF program and further evaluation in a longer-duration study LA JOLLA, CA, September 8, 2026 -- GRI Bio, Inc. (NASDAQ: GRI) ("G…
Open exhibit ↗